Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gsα

Neuropsychopharmacology

Volumn 29, Issue 3, 2004, Pages 494-501

  Gould, Thomas J ^a   Bizily, Scott P ^b,c   Tokarczyk, Jan ^c   Kelly, Michele P ^b,c   Siegel, Steven J ^c   Kanes, Stephen J ^c   Abel, Ted ^b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Animal model; G proteins; Prepulse inhibition; Protein kinase A; Schizophrenia; Startle response

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN) II;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FOREBRAIN; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX; TRANSGENIC MOUSE;

ACOUSTIC STIMULATION; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; STARTLE REACTION;

EID: 1642320064     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300309     Document Type: Article

References (66)

1. Abel T, Bourtchouladze R, Patterson SL, Barad M, Winder V, Deuel TA et al (1997a). Transgenic mice expressing a constitutively active form of GalphaS exhibit learning deficits and enhanced synaptic transmission. Soc Neurosci Abstr 23: 1177.
2. Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R (1997b). Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88: 615-626.
3. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982). Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17: 639-654.
4. Andreasen NC, Black DW (1995). Introductory Textbook of Psychiatry. American Psychiatric Press: Washington, DC.
5. Avissar S, Roitman G, Schreiber G (2001). Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cell Mol Neurobiol 21: 799-811.
6. Baruch I, Hemsley DR, Gray JA (1988). Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176: 598-606.
7. Bassett AS, Chow EW, Weksberg R (2000). Chromosomal abnormalities and schizophrenia. Am J Med Genet 97: 45-51.
8. Boutros NN, Zouridakis G, Overall J (1991). Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22: 40-45.
9. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258.
10. Bucan M, Abel T (2002). The mouse: genetics meets behaviour. Nat Rev Genet 3: 114-123.
11. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL (2000). Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157: 1660-1668.
12. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T et al (2002). Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11: 1373-1380.
13. Clegg C, Correll LA, Cadd GG, McKnight GS (1987). Inhibition of intracellular cAMP-dependent protein kinase using mutant genes of the regulatory type I subunit. J Biol Chem 262: 13111-13119.
14. Clementz BA, Geyer MA, Braff DL (1997). P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 41: 1035-1044.
15. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J et al (2003). Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2 Hsd inbred mouse substrains. Brain Research, (in press).
16. Dulawa SC, Hen R, Scearce-Levie K, Geyer MA (1997). Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl) 132: 125-134.
17. Dulawa SC, Hen R, Scearce-Levie K, Geyer MA (1998). 5-HT1B receptor modulation of prepulse inhibition: recent findings in wild-type and 5-HT1B knockout mice. Ann NY Acad Sci 861: 79-84.
18. Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE (1991). Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 30: 430-442.
19. Feldon J, Weiner I (1991). The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29: 635-646.
20. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M et al (1996). Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch Gen Psychiatry 53: 1114-1121.
21. Geyer MA, Braff DL (1987). Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13: 643-668.
22. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117-154.
23. 2+ influx requires cAMP-dependent protein kinase in PC12 cells. J Biol Chem 266: 17454-17458.
24. Ginty DD, Glowacka D, DeFranco C, Wagner JA (1991b). Nerve growth factor-induced neuronal differentiation after dominant repression of both Type I and Type II cAMP-dependent protein kinase activities. J Biol Chem 266: 15325-15333.
25. Gould TJ, Abel T (2000). Transgenic mice that overexpress a constitutively active form of Gas have disrupted prepulse inhibition. Soc Neurosci Abstr 26: 1538.
26. Hoffman DC, Donovan H (1994). D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology (Berl) 115: 447-453.
27. Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR et al (2001). Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 115: 1129-1144.
28. Judd LL, McAdams L, Budnick B, Braff DL (1992). Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 149: 488-493.
29. Kelly MP, Tokarczyk J, Rapoport DA, Godfrey M, Kanes SJ, Abel T (2003). Modeling cognitive deficits of schizophrenia in mice with altered G-protein signaling. Soc Neurosci Abstr 29: 858.2.
30. Kline L, Decena E, Hitzemann R, McCaughran Jr J (1998). Acoustic startle, prepulse inhibition, locomotion, and latent inhibition in the neuroleptic-responsive (NR) and neuroleptic-nonresponsive (NNR) lines of mice. Psychopharmacology (Berl) 139: 322-331.
31. Koch M (1999). The neurobiology of startle. Prog Neurobiol 59: 107-128.
32. Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94: 507-514.
33. Martinez DL, Geyer MA (1997). Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine. Neuropsychopharmacology 16: 246-255.
34. Mayford M, Baranes D, Podsypanina K, Kandel ER (1996). The 3′ untranslated region of CaMKIIα in a cis-acting signal for the localization and translation of mRNA in dendrites. Proc Natl Acad Sci USA 93: 13250-13255.
35. Mellon PL, Clegg CL, Correll LA, McKnight GS (1989). Regulation of transcription by cyclic AMP-dependent protein kinase A. Proc Natl Acad Sci USA 86: 4887-4891.
36. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6: 293-301.
37. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.
38. 3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res 615: 41-49.
39. Okada F, Crow TJ, Roberts GW (1991). G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J Neural Transm Gen Sect 84: 147-153.
40. Okada F, Tokumitsu Y, Takahashi N, Crow TJ, Roberts GW (1994). Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain. J Neural Transm Gen Sect 95: 95-104.
41. Owen MJ (2000). Molecular genetic studies of schizophrenia. Brain Res Brain Res Rev 31: 179-186.
42. Peng RY, Mansbach RS, Braff DL, Geyer MA (1990). A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3: 211-218.
43. Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M et al (1999). The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19: 4627-4633.
44. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA (2003). Dopamine d1 rather than d2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28: 108-118.
45. Rigdon GC, Weatherspoon JK (1992). 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther 263: 486-493.
46. Rund BR, Borg NE (1999). Cognitive deficits and cognitive training in schizophrenic patients: a review. Acta Psychiatr Scand 100: 85-95.
47. Sawa A, Snyder SH (2002). Schizophrenia: diverse approaches to a complex disease. Science 296: 692-695.
48. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM et al (1991). Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48: 618-624.
49. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P et al (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131.
50. Sipes TA, Geyer MA (1994). Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33: 441-448.
51. Sipes TA, Geyer MA (1995a). 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology (Berl) 117: 41-48.
52. Sipes TE, Geyer MA (1995b). DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. Behav Pharmacol 6: 839-842.
53. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981). Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16: 519-537.
54. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ et al (1996). Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15: 152-162.
55. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139-154.
56. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA et al (2002). Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) 161: 189-201.
57. Swerdlow NR, Geyer MA (1998). Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24: 285-301.
58. Tarantino LM, Bucan M (2000). Dissection of behavior and psychiatric disorders using the mouse as a model. Hum Mol Genet 9: 953-965.
59. Tarantino LM, Gould TJ, Druhan JP, Bucan M (2000). Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mamm Genome 11: 555-564.
60. Wan FJ, Taaid N, Swerdlow NR (1996). Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 14: 265-274.
61. Wand G, Levine M, Zweifel L, Schwindinger W, Abel T (2001). The cAMP-protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. J Neurosci 21: 5297-5303.
62. Weickert CS, Kleinman JE (1998). The neuroanatomy and neurochemistry of schizophrenia. Psychiatr Clin North Am 21: 57-75.
63. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40: 834-843.
64. Woo NH, Abel T, Nguyen PV (2002). Genetic and pharmacological demonstration of a role for cyclic AMP-dependent protein kinase-mediated suppression of protein phosphatases in gating the expression of late LTP. Eur J Neurosci 16: 1871-1876.
65. Woo NH, Duffy SN, Abel T, Nguyen PV (2000). Genetic and pharmacological demonstration of differential recruitment of cAMP-dependent protein kinases by synaptic activity. J Neurophysiol 84: 2739-2745.
66. Yang CQ, Kitamura N, Nishino N, Shirakawa O, Nakai H (1998). Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol Psychiatry 43: 12-19.